<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711772</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2020-188</org_study_id>
    <nct_id>NCT04711772</nct_id>
  </id_info>
  <brief_title>Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve</brief_title>
  <official_title>A Whole-genome Sequencing Base Study on Genetic Pathogenesis of Diminished Ovarian Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the genetic pathogenesis of diminished ovarian reserve via&#xD;
      whole-genome sequencing technology in Chinese women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diminished ovarian reserve (DOR), a pathological condition of reduced quantity and quality of&#xD;
      oocytes, has severe impairment on women fertility. Some women experience DOR may develop into&#xD;
      premature ovarian insufficiency (POI), which defined as a cessation of function of ovaries in&#xD;
      women younger than 40 years old. The pathogenesis of DOR is multiple and the etiology of most&#xD;
      DOR remains obscure. Genetic factors, including chromosome abnormality, genetic variation,&#xD;
      and non-coding RNA abnormal regulation are considered the major mechanisms of DOR. More than&#xD;
      12 gene mutations, detected by whole-exome sequencing (WES), have been implicated as&#xD;
      potential causes of DOR. However, we have found that coding gene mutation detected by WES may&#xD;
      only account for a small part of DOR. Whole-genome sequencing (WGS) has been developing into&#xD;
      an important strategy for identifying exons, introns and mitochondrial DNA mutation. However,&#xD;
      the application of WGS is still lacking in detecting pathogenic genes of DOR. Therefore, this&#xD;
      study intends to explore the possible pathogenic genes by WGS in order to deeply and&#xD;
      comprehensively understand the pathogenic mechanism of DOR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype</measure>
    <time_frame>1/9/2020-31/12/2022</time_frame>
    <description>Measure the genotype by whole-genome sequencing in all participates.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Diminished Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>DOR group</arm_group_label>
    <description>Genomic DNA will be extracted from peripheral blood leukocytes to perform whole-genome sequencing in participates with diminished ovarian reserve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Participants with normal ovarian reserve will be recruited as control group and peripheral blood leukocytes genomic DNA will be extracted to perform whole-genome sequencing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>whole-genome sequencing</intervention_name>
    <description>Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>DOR group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples(10 ml) will be collected(in EDTA anticoagulant tube) and an informed&#xD;
      consent form will be signed for participates diagnosed with DOR and control women.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The two groups of this study consist of DOR patients and women with normal ovarian reserve.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DOR group:&#xD;
&#xD;
          1. age between 18 and 40 years;&#xD;
&#xD;
          2. number of oocytes obtained in previous ovarian stimulation cycles ≤3;&#xD;
&#xD;
          3. bilateral ovarian antral follicle count (AFC) &lt; 5-7;&#xD;
&#xD;
          4. serum anti-Mullerian hormone (AMH) &lt;0.5-1.1ng/ml.&#xD;
&#xD;
        Control group:&#xD;
&#xD;
          1. age between 18 and 40 years;&#xD;
&#xD;
          2. bilateral AFC ≥8;&#xD;
&#xD;
          3. serum AMH ≥1.2ng/ml;&#xD;
&#xD;
          4. regular menstrual cycles occurring every 25-35 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The exclusion criteria of the two groups were:&#xD;
&#xD;
          1. an abnormal karyotype;&#xD;
&#xD;
          2. a history of other endocrine diseases such as polycystic ovary syndrome,&#xD;
             hyperprolactinemia and hyperthyroidism;&#xD;
&#xD;
          3. a history of radiotherapy, chemotherapy and ovarian surgery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi-ling Chen, M.D, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shi-ling Chen, M.D, Ph.D</last_name>
    <phone>+86-020-62787604</phone>
    <email>chensl_92@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Shi-Ling, M.D., Ph.D</last_name>
      <phone>+86-20-62787604</phone>
      <email>chensl_92@163.com</email>
    </contact>
    <investigator>
      <last_name>Chen Shi-Ling, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diminished Ovarian Reserve</keyword>
  <keyword>Whole-genome Sequencing</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

